The British Land Company (BLDA) Q4 2026 Earnings Report

The call presented a materially positive operational and financial picture: record leasing, strong ERV and like‑for‑like rent growth, improved occupancy, accretive M&A and a healthy balance sheet underpin confidence in FY27 earnings and mid-term targets. Headwinds include higher finance costs, margin drag from voids and one-off provision movements, development timing/regulatory delays and market volatility on financing. On balance the operational outperformance and visible earnings derisking outweigh the noted challenges.

The group guided to 8–10% through‑the‑cycle total accounting returns and ERV growth of 3–5% (like‑for‑like rental growth also guided at 3–5%, expected at the top end in FY27), and reiterated at least 30.5p EPS for FY27 (c.6% growth). Management expects c.£40m of development rents in FY27, a FY27 cost ratio around 17.5% (admin costs down 9% year‑on‑year and 16% since 2022) with margins targeted to return toward ~90% over time, and a modest further rise in finance costs of c.10–20bps given the hedging profile (94% hedged today, falling to ~70% over five years). Balance‑sheet guidance: LTV 39.2%, net debt/EBITDA 7.7x, £1.6bn liquidity, no refinancing requirement until 2029; portfolio values rose 2.3% and NTA was 590p (+4%). Operational metrics cited to support the outlook included ERV growth (portfolio 4.9%; Campuses +6.5%; Retail & Urban Logistics +3.6%), record Campus leasing of 1.7m sq ft (Campus occupancy 95%, Retail occupancy 99%), 295k sq ft under offer at year‑end (plus 228k sq ft post year‑end), and the Life Science REIT deal, which is NTA‑neutral, immediately adds c.0.3p to FY27 EPS (acquisition costs ~£10m).